Lv12
40 积分 2022-08-03 加入
Molecular Subtype Changes After Acquiring Resistance to Tarlatamab in Small Cell Lung Cancer
4分钟前
待确认
Small cell lung cancer
58分钟前
已完结
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin
1天前
已完结
New immune cell engagers for cancer immunotherapy
1个月前
已完结
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
1个月前
已完结
Transferrin Receptor Targeting Chimeras (TransTACs) for Membrane Protein Degradation
1个月前
已完结
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
2个月前
已完结
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
2个月前
已完结
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
2个月前
已完结
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
2个月前
已完结
皖公网安备34019202002308
